Search
for
Sort by
Research 271–300 of 1000+
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
- Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Human hair follicle transcriptome profiling: a minimally invasive tool to assess molecular adaptations upon low‐volume, high‐intensity interval training
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
- JAK inhibition decreases the autoimmune burden in Down syndrome
- 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
- NF-κB in biology and targeted therapy: new insights and translational implications
- Ritlecitinib (Litfulo)
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study
- Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis
- Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways
- Irish dermatologists’ experience with JAK inhibitors in alopecia areata
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
- Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
- Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus